Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators..

N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.

2.

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP.

PLoS One. 2008 Jul 9;3(7):e2636. doi: 10.1371/journal.pone.0002636.

3.

A case of recurrent sterile abscesses following vaccination: delayed hypersensitivity to aluminum.

Lehman HK, Faden HS, Fang YV, Ballow M.

J Pediatr. 2008 Jan;152(1):133-5. No abstract available.

PMID:
18154915
4.

The use of oil adjuvants in therapeutic vaccines.

Aucouturier J, Ascarateil S, Dupuis L.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-44-5.

PMID:
16823921
5.

Revisiting Freund's incomplete adjuvant for vaccines in the developing world.

Miller LH, Saul A, Mahanty S.

Trends Parasitol. 2005 Sep;21(9):412-4. Review.

PMID:
16043410
6.

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.

Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V.

Expert Rev Vaccines. 2002 Jun;1(1):111-8.

PMID:
12908518
7.

A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.

Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W.

Vaccine. 2001 Apr 30;19(23-24):3033-42.

PMID:
11311997
8.

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Letvin NL, Robinson S, Rohne D, Axthelm MK, Fanton JW, Bilska M, Palker TJ, Liao HX, Haynes BF, Montefiori DC.

J Virol. 2001 May;75(9):4165-75.

9.

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine.

Gahéry-Ségard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, Tartar A, Lévy JP, Gras-Masse H, Guillet JG.

J Virol. 2000 Feb;74(4):1694-703.

10.

HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients.

Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, Ahlers J, Dunlop N, Cohen RB, Steinberg SM, Nara P, Shearer GM, Yarchoan R.

AIDS. 1999 Oct 22;13(15):2003-12.

PMID:
10546852
11.

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.

Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF.

AIDS. 1998 Jul 30;12(11):1291-300.

PMID:
9708408
12.

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, Weinhold KJ.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1396-401.

13.

Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes.

Alexander-Miller MA, Parker KC, Tsukui T, Pendleton CD, Coligan JE, Berzofsky JA.

Int Immunol. 1996 May;8(5):641-9.

PMID:
8671651
15.

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE.

J Infect Dis. 1996 Feb;173(2):330-9.

PMID:
8568293
16.

Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.

Haynes BF, Torres JV, Langlois AJ, Bolognesi DP, Gardner MB, Palker TJ, Scearce RM, Jones DM, Moody MA, McDanal C, et al.

J Immunol. 1993 Aug 1;151(3):1646-53.

PMID:
8335949
17.

Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.

Haynes BF, Yasutomi Y, Torres JV, Gardner MB, Langlios AJ, Bolognesi DP, Matthews TJ, Scearce RM, Jones DM, Moody MA, et al.

Trans Assoc Am Physicians. 1993;106:33-41. No abstract available.

PMID:
8036743
18.

Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.

Trauger RJ, Ferre F, Daigle AE, Jensen FC, Moss RB, Mueller SH, Richieri SP, Slade HB, Carlo DJ.

J Infect Dis. 1994 Jun;169(6):1256-64.

PMID:
7910836
19.

Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys.

Yasutomi Y, Palker TJ, Gardner MB, Haynes BF, Letvin NL.

J Immunol. 1993 Nov 1;151(9):5096-105.

PMID:
7691965
20.

Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.

Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S74-82.

PMID:
7552517

Supplemental Content

Support Center